NICE finally approves Stelara for psoriatic arthritis

[Bill]

I have heard it said that if patients were prescribed out of patent medicines that had equal or better efficacy than the patented drugs, medicines would be 95% cheaper. With such savings it might be possible to supply the best therapy first instead of second rate ones. The mark up on DMF is over 100 times and the pharmaceutical formulations are no better in my opinion, and perhaps even less so than the raw stuff. The proportion of psoriasis sufferers unresponsive to the cheaper therapies cannot be very great. It would be nice to see people properly treated instead of stuffed around by an inefficient allocation of funds.

Cheers,

Bill